"Istituto pienamente integrato nel sistema sanitario pubblico dell’Ente Ospedaliero . Oggi, il Cardiocentro non è solo è un presidio irrinunciabile sul territorio per la prevenzione e la cura della patologia cardiaca, ma una realtà di prestigio internazionale, protagonista nella ricerca e fortemente impegnata nella formazione, con importanti e costanti relazioni mediche e scientifiche con rinomati istituti universitari e di ricerca in Svizzera e nel mondo."

During the past decade, Cardiocentro Ticino conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 13 clinical trials were completed, i.e. on average, 38.2% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 9 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cardiocentro Ticino" #1 sponsor was "Cardiocentro Ticino" with 5 trials, followed by "Abbott Medical Devices" with 3 trials sponsored, "Biotronik SE & Co. KG" with 3 trials sponsored, "University of Zurich" with 3 trials sponsored and "Biotronik AG" with 3 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cardiocentro Ticino" #1 collaborator was "University of Bern" with 2 trials as a collaborator, "A.O.U. Città della Salute e della Scienza - Molinette Hospital" with 1 trials as a collaborator, "Albany Stratton VA Medical Center" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia" with 1 trials as a collaborator. Other collaborators include 117 different institutions and companies that were collaborators in the rest 127 trials.

According to Clinical.Site data, the most researched conditions in "Cardiocentro Ticino" are "Coronary Artery Disease" (13 trials), "Heart Failure" (12 trials), "Atrial Fibrillation" (6 trials), "Acute Myocardial Infarction" (3 trials) and "Myocardial Ischemia" (3 trials). Many other conditions were trialed in "Cardiocentro Ticino" in a lesser frequency.

Most popular intervention types in "Cardiocentro Ticino" are "Device" (30 trials), "Drug" (17 trials), "Procedure" (7 trials), "Other" (3 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "XIENCE V®/ XIENCE PRIME™" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Abbott Laboratories Xience" (1 trials) and "Ablation" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cardiocentro Ticino" are 61 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Cardiocentro Ticino". undefined are not yet recruiting, 10 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 35 completed trials in Cardiocentro Ticino, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Cardiocentro Ticino, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 20 trials that are defined as “Not Applicable".